Reasons for this may include that survivin is not in all cell lines the major therapeutic target of YM155 as it is in neuroblastoma cells [1,2,3,4,5,6,7,8,9,10,11,12,16,36] and/or that off-target resistance mechanisms, such as ABCB1 and SLC35F2 expression, may affect YM155 efficacy independently of the survivin status [14,16,17,35]. The gene discussed is SLC35F2; the disease is neuroblastoma.